Abbvie Inc.

Abbott Laboratories Corporation

Rajarathnam E Reddy

Sanjay R Chemburkar

Michael J Abrahamson

Angelica B Kielbus

Julie J Pruyne

John E Lallaman

William T Riordan

Donald D Johnson

David R Hill

Jianzhang Mei

Shelley R Holets-McCormack

Timothy B Towne

Lei Cao

Brian J Kotecki

Thomas G Spring

Elaine Marie Brate

Yon-Yih Chen

Douglas M Reamer

You Pan

John Pavlina

Stephen S Ulrey

Gareth J Brown

Stefan Mix

Jose A Restituyo

Douglas R Spaulding

Richard Lorenzini

Michael Demarco

Yi Pan

Disclosed herein is a process for preparing enantioenriched (S)-2-aminonon-8-enoic acid by amination of 2-oxonon-8-enoic acid in the presence of an enzyme and an ammonia source.

Process for the preparation of (S)-2-amino-non-8-enoic acid

Disclosed are methods of synthesizing enantioenriched difluoroalkylcyclopropyl amino esters and their salts, such as the dicyclohexylamine salt of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropane carboxylic acid. These compounds are useful intermediates in the synthesis of viral protease inhibitors.

Enzymatic process for the preparation of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropanecarboxylic acid

Disclosed are, among other things, variant polypeptides, nucleic acids encoding the polypeptides, production of the variant polypeptides, and use of the variant polypeptides in various applications, such as screening and synthetic methods. For example, the variant polypeptides, or enzymatically-active fragments thereof, are useful for converting aliphatic keto acids to aliphatic alpha amino acids.

Variant polypeptides capable of aminating aliphatic alpha keto acids

A process for the preparation of (2S,3aR,7aS)-octahydro-1H-indole-20carboxylic acid hydrochloride.

Process for the synthesis of (2S,3AR,7AS)-octahydro-1H-indole carboxylic acid as an intermediate for trandolapril

Methods and kits for measurement of concentration of FK778 in a biological sample by means of an immunoassay, preferably a competitive immunoassay. In one aspect, the method and kit involve the use of (a) an antibody to FK778 conjugated to a label, e.g., an acridinium label, (b) an antibody to FK778 not conjugated to a label, (c) a solid phase containing an antibody to a first hapten, e.g., a fluorescein hapten, and (d) a bihapten comprising a first hapten and FK778 or an analogue of FK778, e.g., a bihapten comprising a fluorescein hapten and a FK778 hapten. In another aspect, the method and kit involve the use of (a) antibody to FK778, (b) a bihapten comprising FK778 or an analogue of FK778 and a first hapten, e.g., a bihapten comprising the fluorescein hapten and the hapten of FK778 or an analogue of FK778, and (c) a pretreatment reagent.

Determination of concentration of FK778 by competitive immunoassay

Growing community of inventors

Gurnee, IL, United States of America

Rajarathnam E Reddy